Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 13/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 13/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.34 |
| ▸ | CLK2 | P49760 | 4/20 | 0.34 |
| ▸ | CLK3 | P49761 | 4/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16776383 | 0.92 | DYRK1A (0.35) | PRMT5WDR77CLK2CLK3DYRK1A | |
| SCHEMBL16776397 | 0.90 | RPS6KA3 (0.40) | AR | |
| SCHEMBL16776393 | 0.85 | AR (0.34) | ARDYRK1A | |
| SCHEMBL16785562 | 0.84 | RPS6KA3 (0.38) | — | |
| SCHEMBL16776399 | 0.83 | CREBBP (0.42) | BRD4CREBBPDYRK1A | |
| SCHEMBL16776395 | 0.80 | TRPA1 (0.33) | — | |
| SCHEMBL16776388 | 0.80 | NPC1 (0.38) | CLK2CLK3DYRK1A | |
| SCHEMBL16776389 | 0.79 | PIK3CA (0.33) | — | |
| SCHEMBL16776387 | 0.79 | PTGS1 (0.35) | PRMT5WDR77ARDYRK1A | |
| SCHEMBL16776394 | 0.78 | FAAH (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | PRMT5 209/4885WDR77 1434/4885BRD4 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.